✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the belinostat profile page.
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 206256
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 206256
|Mechanism of Action|| Histone Deacetylase Inhibitors |
Suppliers and Packaging for NDA: 206256
Profile for product number 001
|Approval Date:||Jul 3, 2014||TE:||RLD:||Yes|
|Patent:||See Plans and Pricing||Patent Expiration:||Aug 10, 2026||Product Flag?||Y||Substance Flag?||Y||Delist Request?|
|Patented Use:||TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).|
|Patent:||See Plans and Pricing||Patent Expiration:||Oct 27, 2027||Product Flag?||Y||Substance Flag?||Delist Request?|
Complete Access Available with Subscription